TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06221683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homoharringtonine
Description: 3mg/m2/day for weighing \>10kg, 0.1mg/kg/day for weighing ≤10kg, d1-7, ivgtt, qd, more than 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100mg/m2/q12h for weighing \>10kg, 3.3mg/kg/q12h for weighing ≤10kg, d1-7, ivgtt, q12h, more than 30 minutes in SDC group; 10mg/m2/q12h for weighing \>10kg, 0.33mg/kg/q12h for weighing ≤10kg, d1-10, s.c.,q12h (the first dose at 8 am) in the LDC group;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100mg/m2/q12h for weighing \>10kg, 3.3mg/kg/q12h for weighing ≤10kg, d1-7, ivgtt, q12h, more than 30 minutes in SDC group; 10mg/m2/q12h for weighing \>10kg, 0.33mg/kg/q12h for weighing ≤10kg, d1-10, s.c.,q12h (the first dose at 8 am) in the LDC group;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100mg/m2/d for weighing \>10kg, 3.3mg/kg/d for weighing ≤ 10kg, d1-5, ivgtt, qd, more than 4 hours
Study: NCT05761431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX2008 injection
Description: Subcutaneous administration on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX2008 injection
Description: Subcutaneous administration on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX2008 injection
Description: Subcutaneous administration on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX2008 injection
Description: Subcutaneous administration on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate Microspheres for Injection injection
Description: Intramuscular administration on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin ® injection
Description: Subcutaneous administration on Day 1.
Study: NCT06221683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: 100mg/m2/d for weighing \>10kg, 3.33mg/kg/d for weighing ≤10kg, d12-25, po, qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome
Description: 5mg/m2/d for weighing \>10kg, 0.17mg/kg/d for weighing ≤ 10kg, d1, 3, 5, ivgtt, qod, more than 2 hours at 10 am.
Study: NCT05761431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to SYHX2008 injection
Description: Subcutaneous administration on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to SYHX2008 injection
Description: Subcutaneous administration on Day 1.
Study: NCT06221683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Granulocyte Colony-Stimulating Factor
Description: 5ug/kg/d, d1-10, s.c., qd, at 1pm
Study: NCT05761431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to SYHX2008 injection
Description: Subcutaneous administration on Day 1.
Study: NCT06221683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin Hydrochloride
Description: 3mg/m2/day for weighing \>10kg, 0.1mg/kg/day for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 6 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 100mg/m2/day for weighing \>10kg, 3.3mg/kg/day for weighing ≤10kg, from identification, po, qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 100mg/m2/day for weighing \>10kg, 3.3mg/kg/day for weighing ≤10kg, from identification, po, qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: 20mg/m2/day for weighing \>10kg, 0.7mg/kg/day for weighing ≤ 10kg, from identification, po, qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: 20mg/m2/day for weighing \>10kg, 0.7mg/kg/day for weighing ≤ 10kg, from identification, po, qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: 50mg/m2/day for weighing bodyweight \>10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: 50mg/m2/day for weighing bodyweight \>10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd
Study: NCT05235737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Adding Pembrolizumab as a neoadjuvant and adjuvant therapy to the standard of care protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Adding Pembrolizumab as a neoadjuvant therapy to the standard of care protocol
Study: NCT04791865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disclosure intervention
Description: Participants who are assigned to the Sankofa intervention will take part in the process of disclosure (pre-disclosure, disclosure, and post-disclosure phases) with the adherence and disclosure specialist (ADDS).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: During the control period, patients and caregivers recruited at the clinics will receive the current practice in the clinic, where the health care provider is expected to assess the caregiver and child readiness for disclosure during clinic appointments and give some information as they think indicated.
Study: NCT05921331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The RJBC-APP
Description: The RJBC-APP consists of the following features: 1. Login, logout, setting, and modification of personal information. 2. Full-course management included registering for information on the surgical treatment, viewing the results of the multidisciplinary team (MDT) discussion, generating the treatment process according to the MDT discussion, receiving the reminder of the treatment, confirming the completion of the treatment, filling in the follow-up information, and consulting a specialist nurse. 3. Questionnaire and feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine post-surgical follow-up
Description: The routine post-surgical follow-up is conducted in the outpatient clinic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine post-surgical follow-up
Description: The routine post-surgical follow-up is conducted in the outpatient clinic.
Study: NCT05591352

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chenopodium formosanum extracts sachet
Description: consume 1 sachet per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sachet
Description: consume 1 sachet per day
Study: NCT06496893

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IP 1200 mg per soft gel capsule
Description: Two soft gels to be taken with breakfast and two soft gels to be taken with dinner

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo 1200 mg per soft gel capsule
Description: Two soft gels to be taken with breakfast and two soft gels to be taken with dinner
Study: NCT04393883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;
Description: (A) Standard maintenance programme group, pembrolizumab 200mg, every 3 weeks, for a total of 2 years of follow-up and follow-up for 1 year;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
Description: (B) Improvement maintenance programme group, pembrolizumab 200mg, every 6 weeks, for a total of 2 years of follow-up and 1 year follow-up;
Study: NCT04326491

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath Biopsy
Description: Analysis of breath samples to identify volatile molecules specific to HCC

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath Biopsy
Description: Analysis of breath samples to identify volatile molecules specific to HCC
Study: NCT04827004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsules
Description: Anlotinib capsules given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
Study: NCT05416359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3915 tablets
Description: TQB3915 binds to estrogen receptors through covalent bonds, and blocks intracellular signal transmission by changing the conformation of ERα, thereby inhibiting the growth of tumor cells.
Study: NCT06084273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bobath Exercises
Description: The Bobath approach aims to enhance postural and neuromotor control goal-directedly, leading to functional improvement. Our study selected the Bobath 30 exercises from the fundamental exercises to create a program specific to the goal and targeting functionality.~The ten Bobath exercises performed by all participants in the study are as follows: Bridging Exercise, Latissimus Stretch Exercise, Autoinhibition Exercise, Dorsiflexion Training, Sitting Balance Training, Upper Extremity Weight Shifting Exercise, Lower Extremity Weight Shifting Exercise, Oblique Abdominal Strengthening Exercise, Knee Control Training, and Walking Training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bobath Exercises
Description: The Bobath approach aims to enhance postural and neuromotor control goal-directedly, leading to functional improvement. Our study selected the Bobath 30 exercises from the fundamental exercises to create a program specific to the goal and targeting functionality.~The ten Bobath exercises performed by all participants in the study are as follows: Bridging Exercise, Latissimus Stretch Exercise, Autoinhibition Exercise, Dorsiflexion Training, Sitting Balance Training, Upper Extremity Weight Shifting Exercise, Lower Extremity Weight Shifting Exercise, Oblique Abdominal Strengthening Exercise, Knee Control Training, and Walking Training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercises,Breathing Exercises, Bobath Exercises
Description: The puckered lip breathing exercise aims to prevent the closure of the small airways by creating pressure during expiration. During the exercise, the individual is asked to follow these steps:~1. Breathe calmly and slowly through the nose.~2. Pucker the lips as if whistling or inflating a balloon.~3. Exhale the breath with puckered lips. Relaxation exercises Progressive Muscle Relaxation Technique: Progressive muscle relaxation is one of the easiest methods to learn and apply, developed by Jacobson. It involves voluntarily tensing and relaxing large muscle groups regularly and sequentially. The participant was encouraged to wear comfortable clothing, breathe deeply, and exhale. The technique can be performed in a sitting or lying position. Music can be played to contribute to the participant's relaxation.
Study: NCT06272812

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC
Description: Vaccine Dose: MTBVAC 5x10\^5 Formulation (approximately, per standard dose): 3 - 17x10\^5 CFU Sucrose Sodium glutamate Presentation: Lyophilized pellet in vials (10 doses) Volume: 0.1 mL/dose Intradermal

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline Volume: 0.1 mL/dose Intradermal
Study: NCT05021328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240mg, ivgtt, d1, q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12 mg/d, d1-14, q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12 mg/d, d1-14, q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBRT 7Gy✖️5 QD
Description: SBRT 7Gy✖️5 QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBRT 7Gy✖️5 QD
Description: SBRT 7Gy✖️5 QD
Study: NCT04953208

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: Treatment will be applied daily 5 days/week for a period of 6 weeks, which equals a tDCS stimulation for a total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: sham stimulation for a total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive and emotional control video game
Description: a video game targeting cognitive and emotional control. total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham video game
Description: a video game which does not target cognitive control, played for total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.
Study: NCT05538169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level laser diode (Pioon Laser)
Description: Settings: the spot tip area of this tool is 0.088 cm2, semi-conductor diode, with a wavelength of 980 nm (near infrared), 200 mW output power, 1.97W/cm2 of power density, 3 J energy per point and application time 15 seconds per point\].~* PBM will apply punctually, in continuous emissions.~* Extra-oral points: six points on each parotid gland, three points on each submandibular gland.~* Intra-oral points: two points on each sublingual gland.~* A total of 22 points will be applied in each session.
Study: NCT06497361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRG-2311
Description: PRG-2311 (CD19/BCMA-targeting CAR-T Cells)
Study: NCT05465707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313 2 mg/kg
Description: Once 1 week, intravenous infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313 4 mg/kg
Description: Once 1 week, intravenous infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313 8 mg/kg
Description: Once 1 week, intravenous infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313 16 mg/kg
Description: Once 1 week, intravenous infusion.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once 1 week, intravenous infusion.
Study: NCT05335837

Intervention type: PROCEDURE
Intervention: Regional Anesthesia and Sedation
Description: Preoperative ilioinguinal/iliohypogastric nerve block and moderate to deep intraoperative sedation.
Study: NCT06381206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: Selective Alpha Blocker drug
Study: NCT05368844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS treatment using BrainsWay Model 104 system with H1-Coil
Description: 5 days of 10 daily sessions of rTMS treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham TMS using BrainsWay Model 104 system with H1-Coil
Description: 5 days of 10 daily sessions of sham iTBS treatment
Study: NCT04166474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dosed at 50 mg bd on 3 separate occasions with low, medium and high doses of rifampicin. Dosed at 50 mg od without rifampicin.
Study: NCT06478472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib in combination with rituximab
Description: Induction Phase:~Orelabrutinib + rituximab for a total of 6 cycles of 28 days each Obrutinib (O) 150mg oral d1-28 Rituximab (R) 375mg/m2 IV d0~Maintenance phase:~Orelabrutinib 150mg po qd 24 cycles of 28 days each
Study: NCT05481892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellular Home blood pressure (BP) monitoring
Description: Patients receiving intervention will receive cellular home blood pressure (BP) monitoring devices. Some patients will also receive pharmacist support for treatment intervention.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cellular Home blood pressure (BP) monitoring
Description: Patients receiving intervention will receive cellular home blood pressure (BP) monitoring devices. Some patients will also receive pharmacist support for treatment intervention.
Study: NCT05035719

Intervention type: DEVICE
Intervention: non-invasive cardiac output monitor
Description: Equivalence of Caretaker cardiac output reading to reference standard
Study: NCT05413876

Intervention type: OTHER
Intervention: Intermittent cardiopulmonary exercise test
Description: Exercise test with step-change from rest to a relatively low constant workload.

Intervention type: OTHER
Intervention: Intermittent cardiopulmonary exercise test
Description: Exercise test with step-change from rest to a relatively low constant workload.

Intervention type: OTHER
Intervention: Intermittent cardiopulmonary exercise test
Description: Exercise test with step-change from rest to a relatively low constant workload.

Intervention type: OTHER
Intervention: Intermittent cardiopulmonary exercise test
Description: Exercise test with step-change from rest to a relatively low constant workload.

Intervention type: OTHER
Intervention: Incremental cardiopulmonary exercise test
Description: Exercise test with incremental workload until maximal workload.

Intervention type: OTHER
Intervention: Incremental cardiopulmonary exercise test
Description: Exercise test with incremental workload until maximal workload.

Intervention type: OTHER
Intervention: Incremental cardiopulmonary exercise test
Description: Exercise test with incremental workload until maximal workload.

Intervention type: OTHER
Intervention: Incremental cardiopulmonary exercise test
Description: Exercise test with incremental workload until maximal workload.
Study: NCT06273852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBA-0405
Description: Intratumoral microdose injection by the CIVO device.
Study: NCT06462209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ladder training
Description: Players practiced Ladder training for 60 minutes thrice a week for 8 weeks. There are 3 different types of drills. The first types of drills are steady state drills. These drills focus on quickness Endurance and utilize a constant rhythm throughout the ladder. The second types of drills are burst drills. These drills focus on the ability to turn on rapid burst of foot movement.~The third types of drills are elastic response drills. These drills focus on improving the reactive speed components of the lower leg. A standard agility ladder is 15 feet long and 20 inches wide Step.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plyometric training
Description: In plyometric training players practiced for 60 minutes thrice a week for 8 weeks. warm up for 15 minutes , plyometric training for 30 minutes and cool down for 15 minutes
Study: NCT06419673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy and External Beam Radiotherapy
Description: Brachytherapy and External Beam Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy and External Beam Radiotherapy
Description: Brachytherapy and External Beam Radiotherapy
Study: NCT06537271

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: experimental group
Description: Autism awareness, breastfeeding cessation and toilet training knowledge and attitude training guide and weekly training content animation videos will be prepared for the experimental group and uploaded via WhatsApp and training will be provided. All participants will be interviewed face to face before the training and the necessary information about our study will be provided. Feedback will be received from the researcher regarding the videos, and participants in the study will be able to ask their questions via WhatsApp and share digital content in a digital environment. Evaluation will be made by conducting group work with individuals. Reminders such as mobile phone messages will be used. Training will be carried out within an 8-week program. Each week, training videos on the topics prepared in line with the training guide will be prepared and shared via WhatsApp. Feedback will be received by creating interactive communication environments.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Control Group
Description: After the purpose of the study is explained to the control group by the researcher and written and verbal permission is obtained from those who voluntarily agree to participate in the study, the pre-test data will be collected by the researcher.At the end of the training, survey forms will be filled out by the researcher for the control group and post-test data will be collected.
Study: NCT05280873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone, methylprednisolone
Description: Methylprednisolone 2 mg / kg / d+ pirfenidone (starting from 200mg tid, increasing to 600mg tid within one week and maintaining) . Methylprednisolone was reduced according to the researcher's evaluation of the patient's condition and the specific course of treatment was determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 2 mg / kg / d . Methylprednisolone was gradually reduced after the improvement of symptoms and imaging. The treatment course was 6-8 weeks
Study: NCT06542744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training with the Emagina device at home until birth
Description: The subjects will use the device at home according to a series of 3 exercises, 2 sessions per week, followed by a series of 4 exercises, 3 sessions per week starting from D75.
Study: NCT05231811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Pregnant women by the researcher; Foot massage consisting of classical massage techniques will be applied in a room in the clinic reserved for this application. During the massage; A pillow will be placed under the patient's leg and a disposable cover will be placed on the pillow. During the massage, pregnant women will be massaged with baby oil or vaseline cream. The soles of the pregnant women will be rubbed by the practitioner's fingers. The practitioner will make circular movements by applying pressure to the sole of the pregnant woman's feet with her thumb, and will apply pressure to the foot with up and down movements, using the joint protrusions on the upper surface of the hand that she has made into a fist. The heel and ankle will be squeezed between the thumb and forefinger of the researcher and kneaded and the massage will be terminated. During the application, the researcher who performs the massage will pay attention to the precautions applied in the hospital.